Receptor signaling: When dimerization is not enough
暂无分享,去创建一个
[1] D. Engelman,et al. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation , 1997, Oncogene.
[2] C. Heldin,et al. Dimerization of cell surface receptors in signal transduction , 1995, Cell.
[3] W. Alexander,et al. Point mutations within a dimer interface homology domain of c‐Mpl induce constitutive receptor activity and tumorigenicity. , 1995, The EMBO journal.
[4] D. Weiner,et al. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation , 1989, Nature.
[5] B. Bormann,et al. Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor , 1996, Nature Structural Biology.
[6] Ronald W. Barrett,et al. Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin , 1996, Science.
[7] L S Mulcahy,et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. , 1998, Biochemistry.
[8] Robert M. Stroud,et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation , 1998, Nature.
[9] D. Baccanari,et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. , 1997, Science.
[10] Wen He,et al. An antagonist peptide–EPO receptor complex suggests that receptor dimerization is not sufficient for activation , 1998, Nature Structural Biology.
[11] S. Chervitz,et al. Molecular mechanism of transmembrane signaling by the aspartate receptor: a model. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[12] I. Wilson,et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. , 1999, Science.
[13] M. Sternberg,et al. A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. , 1990, Protein engineering.
[14] H. Lodish,et al. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization , 1994, Molecular and cellular biology.
[15] S R Sprang,et al. Structures of the extracellular domain of the type I tumor necrosis factor receptor. , 1996, Structure.
[16] T. Arakawa,et al. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. , 1996, Biochemistry.
[17] I. Wilson,et al. Erythropoietin receptor activation by a ligand-induced conformation change. , 1999, Science.
[18] Enrico A. Stura,et al. Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å , 1996, Science.
[19] J G Gleason,et al. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see commetns]. , 1998, Science.
[20] D. Chang,et al. Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies* , 1996, The Journal of Biological Chemistry.
[21] D. Goeddel,et al. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. , 1999, Science.
[22] A. D. de Vos,et al. Structural basis for cytokine hormone-receptor recognition and receptor activation. , 1998, Advances in protein chemistry.
[23] D. Stern,et al. Activation of Neu (ErbB-2) Mediated by Disulfide Bond-Induced Dimerization Reveals a Receptor Tyrosine Kinase Dimer Interface , 1998, Molecular and Cellular Biology.
[24] S R Sprang,et al. Crystallographic Evidence for Dimerization of Unliganded Tumor Necrosis Factor Receptor (*) , 1995, The Journal of Biological Chemistry.
[25] E. Van Obberghen,et al. Signalling through the insulin receptor and the insulin-like growth factor-I receptor. , 1994, Diabetologia.